[
  {
    "ts": null,
    "headline": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
    "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
    "url": "https://finnhub.io/api/news?id=9a7f693ca872f0729cbe2b9b4392fe525775d2044fa9cba03809fe27fe1bac3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734697620,
      "headline": "Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals",
      "id": 132073302,
      "image": "https://media.zenfs.com/en/zacks.com/afe95824683969079aeba27c8210bd37",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.",
      "url": "https://finnhub.io/api/news?id=9a7f693ca872f0729cbe2b9b4392fe525775d2044fa9cba03809fe27fe1bac3b"
    }
  }
]